Table 1. Demographical and clinical characteristics according to 6-week mortality.
| Characteristics | All patients (n = 714) |
Survivors (n = 621) |
Nonsurvivors (n = 93) |
P-value |
|---|---|---|---|---|
| Age (years) | 54.7 ± 12.7 | 54.5 ± 12.5 | 55.8 ± 14.2 | 0.380 |
| Gender (M/F) | 560/154 | 487/134 | 73/20 | 0.987 |
| History of HCC (%) | 146 (21) | 115 (19) | 31 (33) | 0.001 |
| Causes of cirrhosis | ||||
| Alcoholic | 256 (35) | 230 (37) | 26 (28) | 0.157 |
| Hepatitis B | 92 (13) | 79 (13) | 13 (14) | 0.406 |
| Hepatitis C | 214 (30) | 175 (28) | 39 (42) | 0.663 |
| Alcoholic + Hepatitis B | 48 (7) | 45 (7) | 3 (3) | 0.090 |
| Alcoholic + Hepatitis C | 36 (5) | 34 (6) | 2 (2) | 0.097 |
| Hepatitis B + Hepatitis C | 15 (2) | 14 (2) | 1 (1) | 0.242 |
| Alcoholic + Hepatitis B + Hepatitis C | 13 (2) | 10 (2) | 3 (3) | 0.067 |
| Other causes* | 40 (6) | 34 (6) | 6 (7) | 0.504 |
| MAP (mmHg) | 89.8 ± 20.6 | 91.1 ± 20.8 | 81.1 ± 16.5 | <0.001 |
| Hemoglobin (g/dL) | 9.4 ± 2.4 | 9.5 ± 2.4 | 8.6 ± 2.1 | 0.001 |
| Leucocytes (K/dL) | 8.0 ± 6.0 | 7.5 ± 5.8 | 10.8 ± 6.2 | <0.001 |
| Bilirubin (umol/L) | 4.5 ± 6.0 | 3.7 ± 4.7 | 10.0 ± 9.8 | <0.001 |
| Prothrombin time INR | 1.4 ± 0.7 | 1.4 ± 0.8 | 1.6 ± 0.5 | 0.007 |
| Albumin (g/dL) | 2.9 ± 0.7 | 3.0 ± 0.7 | 2.6 ± 0.5 | <0.001 |
| Creatinine (mg/dL) | 1.4 ±1.5 | 1.2 ± 1.0 | 2.5 ± 2.9 | <0.001 |
| Platelets (K/L) | 106.4 ± 68.8 | 103.3 ± 65.8 | 126.6 ± 83.7 | 0.012 |
| Sodium (mmol/L) | 138.7 ± 45.3 | 139.0 ± 48.6 | 136.7 ± 7.0 | 0.652 |
| Hepatic encephalopathy (grade) | 0.5 ± 0.9 | 0.4 ± 0.8 | 1.6 ± 1.3 | <0.001 |
| SpO2/FiO2 | 454.4 ± 65.7 | 461.1 ± 56.9 | 409.7 ± 96.4 | <0.001 |
| CPT points | 9.3 ± 1.7 | 4.6 ± 1.7 | 9.2 ± 2.5 | <0.001 |
| MELD score | 14.3 ± 8.2 | 12.9 ± 7.0 | 23.4 ± 9.7 | <0.001 |
| CLIF-SOFA score | 5.1 ±2.4 | 4.6 ± 1.7 | 9.2 ± 2.5 | <0.001 |
M, male; F, female; HCC, hepatocellular carcinoma; MAP, mean arterial pressure; INR, international normalized ratio; SpO2, pulse oximetric saturation; FiO2, fractional inspired oxygen; CTP, Child–Turcotte–Pugh; MELD, model for end-stage liver disease; CLIF-SOFA, chronic liver failure-sequential organ failure assessment.
* “Other causes” includes primary biliary cirrhosis, autoimmune hepatitis, and other unknown causes.